How have BMRA shares performed in 2023?

Biomerica's stock was trading at $3.35 at the beginning of the year. Since then, BMRA shares have decreased by 72.2% and is now trading at $0.93. View the best growth stocks for 2023 here .

Are investors shorting Biomerica?

Biomerica saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 360,100 shares, a decline of 13.0% from the October 31st total of 414,100 shares. Based on an average daily volume of 53,600 shares, the days-to-cover ratio is presently 6.7 days. View Biomerica's Short Interest .

When is Biomerica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, January 12th 2024. View our BMRA earnings forecast .

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) announced its quarterly earnings data on Thursday, October, 12th. The company reported ($0.07) EPS for the quarter. The company had revenue of $1.71 million for the quarter. Biomerica had a negative net margin of 114.52% and a negative trailing twelve-month return on equity of 69.43%.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE) , Pfizer (PFE) , Johnson & Johnson (JNJ) , OPKO Health (OPK) , TG Therapeutics (TGTX) , Advanced Micro Devices (AMD) , Co-Diagnostics (CODX) , FuelCell Energy (FCEL) and Trevena (TRVN) .

Who are Biomerica's major shareholders?

Biomerica's stock is owned by a variety of retail and institutional investors. Top institutional investors include Potomac Capital Management Inc. (1.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste and Zackary S Irani. View institutional ownership trends .

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Biomerica Stock Price, News & Analysis (NASDAQ:BMRA)

$0.93

+0.03 (+3.33%)

(As of 11/30/2023 ET)

Compare

Today's Range: $0.89
▼
$0.94
50-Day Range: $0.71
▼
$1.05
52-Week Range: $0.70
▼
$4.04

Volume: 6,514 shs
Average Volume: 97,140 shs
Market Capitalization: $15.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Biomerica Stock (NASDAQ:BMRA)

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

BMRA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BMRA Stock News Headlines

November 23, 2023 | americanbankingnews.com

Biomerica (NASDAQ:BMRA) Stock Crosses Below 200 Day Moving Average of $1.19

November 23, 2023 | americanbankingnews.com

Biomerica (NASDAQ:BMRA) Share Price Crosses Below 200 Day Moving Average of $1.19

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 10, 2023 | tmcnet.com

Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16

November 8, 2023 | finance.yahoo.com

Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups

October 13, 2023 | markets.businessinsider.com

REPEAT - Biomerica Reports First Quarter 2024 Financial Results

October 13, 2023 | finanznachrichten.de

Biomerica, Inc.: Biomerica Reports First Quarter 2024 Financial Results

October 13, 2023 | markets.businessinsider.com

Biomerica Reports First Quarter 2024 Financial Results

November 30, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

September 26, 2023 | tmcnet.com

Dubai Government Grants Insurance Reimbursement for Biomerica's EZ Detect™ Colorectal Disease Screening Test

September 26, 2023 | finance.yahoo.com

Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test

August 28, 2023 | tmcnet.com

Diagnostics Industry Leader Jack Kenny Joins Biomerica's Board of Directors

August 27, 2023 | finance.yahoo.com

Biomerica Full Year 2023 Earnings: US$0.50 loss per share (vs US$0.36 loss in FY 2022)

August 26, 2023 | finanznachrichten.de

Biomerica, Inc.: Biomerica Reports Fiscal 2023 Year End Results

August 25, 2023 | msn.com

Biomerica reports FY results

August 25, 2023 | finance.yahoo.com

Biomerica Reports Fiscal 2023 Year End Results

August 3, 2023 | it.tmcnet.com

CVS Health to Begin Nationwide In-Store Sales of Biomerica's EZ Detect™ Colorectal Disease Screening Test

June 21, 2023 | finance.yahoo.com

Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients

May 21, 2023 | seekingalpha.com

QRTEA, BIOC and AMTX among mid-day movers

May 18, 2023 | it.tmcnet.com

inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology

April 17, 2023 | finance.yahoo.com

Biomerica, Inc. (BMRA) Stock Historical Prices & Data - Yahoo Finance

April 17, 2023 | finance.yahoo.com

Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).

April 15, 2023 | finanznachrichten.de

Biomerica, Inc.: Biomerica Reports Q3 Fiscal 2023 Results

April 14, 2023 | finance.yahoo.com

Biomerica Reports Q3 Fiscal 2023 Results

March 8, 2023 | finance.yahoo.com

Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed

March 7, 2023 | finance.yahoo.com

Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock

March 3, 2023 | finance.yahoo.com

Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock

See More Headlines

Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/12/2023
Today: 11/30/2023
Next Earnings (Estimated): 1/12/2024
Fiscal Year End: 5/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BMRA
CUSIP: N/A
CIK: 73290
Web: www.biomerica.com
Phone: (949) 645-2111
Fax: 949-553-1231
Employees: 62
Year Founded: 1971

Profitability

EPS (Most Recent Fiscal Year): ($0.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,140,000.00
Net Margins: -114.52%
Pretax Margin: -113.19%
Return on Equity: -69.43%
Return on Assets: -54.16%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.63
Quick Ratio: 5.55

Sales & Book Value

Annual Sales: $5.34 million
Price / Sales: 2.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.70 per share
Price / Book: 1.31

Miscellaneous

Outstanding Shares: 16,820,000
Free Float: 14,551,000
Market Cap: $15.47 million
Optionable: Not Optionable
Beta: -0.64

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Zackary S. Irani (Age 57)
Chairman & CEO
Comp: $141.25k
Mr. Allen C. Barbieri (Age 65)
Executive Vice-Chairman of the Board & Corporate Secretary
Comp: $126.25k
Mr. Gary Lu CPA (Age 42)
Principal Accounting Officer & CFO
Comp: $260k
Ms. Lucy Liu Ph.D.
Director of Manufacturing & Technical Operations
Hans Boehringer
Senior Vice President of POC Research & Development
Mr. Robert W. Carlson
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BMRA Stock Analysis - Frequently Asked Questions

How have BMRA shares performed in 2023?: Biomerica's stock was trading at $3.35 at the beginning of the year. Since then, BMRA shares have decreased by 72.2% and is now trading at $0.93.
View the best growth stocks for 2023 here.
Are investors shorting Biomerica?: Biomerica saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 360,100 shares, a decline of 13.0% from the October 31st total of 414,100 shares. Based on an average daily volume of 53,600 shares, the days-to-cover ratio is presently 6.7 days.
View Biomerica's Short Interest.
When is Biomerica's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, January 12th 2024.
View our BMRA earnings forecast.
How were Biomerica's earnings last quarter?: Biomerica, Inc. (NASDAQ:BMRA) announced its quarterly earnings data on Thursday, October, 12th. The company reported ($0.07) EPS for the quarter. The company had revenue of $1.71 million for the quarter. Biomerica had a negative net margin of 114.52% and a negative trailing twelve-month return on equity of 69.43%.

What other stocks do shareholders of Biomerica own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).
Who are Biomerica's major shareholders?: Biomerica's stock is owned by a variety of retail and institutional investors. Top institutional investors include Potomac Capital Management Inc. (1.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste and Zackary S Irani.
View institutional ownership trends.
How do I buy shares of Biomerica?: Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BMRA) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial